Blog

MindMed Co-Founder Dr. Scott Freeman Proposes Value Enhancement Plan

Aug 11 • 2 min read

Today, FCM MM HOLDINGS, LLC announced that it has sent a letter to the Board of Directors of Mind Medicine Inc. (NASDAQ: MNMD) calling on the Board to adopt a new strategic plan proposed by FCM including: refocusing on its core drugs, cutting cash burn, and terminating MindMed’s at-the-money equity offering. FCM is directed and…

PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application

Aug 11 • 2 min read

PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of novel, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the filing of data to support the conversion of a previously submitted provisional patent covering the biosynthetic production of methylated tryptamine derivatives including N,N-dimethyltryptamine and…

New Study Could Lead To Paradigm Shift In The Treatment of Depression

Aug 11 • 6 min read

It is comfortable to believe that science has all the answers and that our medical professionals are acting with a complete understanding of the human body and mind. However, even today when we know more about the world than ever, there is still much that is a mystery. Science, as a pursuit of knowledge and…

Red Light Holland 2022 Audited Year End Results – Bullish vs Bearish: Episode #5

Aug 11 • 1 min read

In this episode of Bullish vs Bearish, Adam Tubero talks about Red Light Holland‘s ($TRIP) 2022 audited year-end results and business highlights. Red Light Holland might be one of the most overlooked psychedelic companies in the sector. But is there a good reason for this? Watch the video below to find out. As always, you…

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Aug 11 • 2 min read

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd., an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561